{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:09:11Z","timestamp":1790208551164,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003206","name":"Alberta Children's Hospital Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003206","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.bneo.2025.100148","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T16:13:25Z","timestamp":1753460005000},"page":"100148","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Targeting CDK9 inhibits the growth of KMT2A-rearranged infant leukemia and demonstrates synergy with menin inhibition"],"prefix":"10.1016","volume":"2","author":[{"given":"Ritul","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunfen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8525-4239","authenticated-orcid":false,"given":"Melanie M.","family":"Frigault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0306-4646","authenticated-orcid":false,"given":"Amy J.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2582-0569","authenticated-orcid":false,"given":"David Spencer","family":"Mangum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke D.","family":"Maese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4573-5118","authenticated-orcid":false,"given":"Norman J.","family":"Lacayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4898-477X","authenticated-orcid":false,"given":"Aru","family":"Narendran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.bneo.2025.100148_bib1","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1056\/NEJMra1400972","article-title":"Acute lymphoblastic leukemia in children","volume":"373","author":"Hunger","year":"2015","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.bneo.2025.100148_bib2","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1182\/blood-2012-03-362608","article-title":"Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel","volume":"120","author":"Creutzig","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bneo.2025.100148_bib3","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.canlet.2019.11.005","article-title":"KMT2A rearranged acute lymphoblastic leukaemia: unravelling the genomic complexity and heterogeneity of this high-risk disease","volume":"469","author":"Forgione","year":"2020","journal-title":"Cancer Lett"},{"issue":"7","key":"10.1016\/j.bneo.2025.100148_bib4","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3324\/haematol.2008.002436","article-title":"The molecular biology of mixed lineage leukemia","volume":"94","author":"Slany","year":"2009","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.bneo.2025.100148_bib5","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.molcel.2006.06.014","article-title":"Controlling the elongation phase of transcription with P-TEFb","volume":"23","author":"Peterlin","year":"2006","journal-title":"Mol Cell"},{"issue":"8","key":"10.1016\/j.bneo.2025.100148_bib6","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/nrm1981","article-title":"Breaking barriers to transcription elongation","volume":"7","author":"Saunders","year":"2006","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"3","key":"10.1016\/j.bneo.2025.100148_bib7","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.molcel.2022.12.006","article-title":"P-TEFb: the master regulator of transcription elongation","volume":"83","author":"Fujinaga","year":"2023","journal-title":"Mol Cell"},{"key":"10.1016\/j.bneo.2025.100148_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.678559","article-title":"CDK9: a comprehensive review of its biology, and its role as a potential target for anti-cancer agents","volume":"11","author":"Anshabo","year":"2021","journal-title":"Front Oncol"},{"issue":"15","key":"10.1016\/j.bneo.2025.100148_bib9","doi-asserted-by":"crossref","first-page":"11651","DOI":"10.1021\/acs.jmedchem.1c01000","article-title":"Changing for the better: discovery of the highly potent and selective CDK9 inhibitor VIP152 suitable for once weekly intravenous dosing for the treatment of cancer","volume":"64","author":"L\u00fccking","year":"2021","journal-title":"J Med Chem"},{"issue":"11","key":"10.1016\/j.bneo.2025.100148_bib10","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1158\/2767-9764.CRC-23-0219","article-title":"Enitociclib, a selective CDK9 inhibitor, induces complete regression of MYC+ lymphoma by downregulation of RNA polymerase II mediated transcription","volume":"3","author":"Frigault","year":"2023","journal-title":"Cancer Res Commun"},{"issue":"6","key":"10.1016\/j.bneo.2025.100148_bib11","doi-asserted-by":"crossref","first-page":"e750","DOI":"10.1097\/MPH.0000000000002697","article-title":"Establishment of a t(11;19), KMT2A rearranged B-ALL cell line for preclinical evaluation and novel therapeutics development for refractory infant leukemia","volume":"45","author":"Sharma","year":"2023","journal-title":"J Pediatr Hematol Oncol"},{"issue":"7","key":"10.1016\/j.bneo.2025.100148_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0102741","article-title":"Aurora kinases as druggable targets in pediatric leukemia: Heterogeneity in target modulation activities and cytotoxicity by diverse novel therapeutic agents","volume":"9","author":"Jayanthan","year":"2014","journal-title":"PLoS One"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2025.100148_bib13","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1182\/blood-2019-131444","article-title":"Establishing a novel in vitro informed precision clinical trial pathway for refractory pediatric leukemia","volume":"134","author":"Zhang","year":"2019","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bneo.2025.100148_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/genes14101916","article-title":"The small-molecule E26-transformation-specific inhibitor TK216 attenuates the oncogenic properties of pediatric leukemia","volume":"14","author":"Sharma","year":"2023","journal-title":"Genes (Basel)"},{"issue":"2","key":"10.1016\/j.bneo.2025.100148_bib34","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.bneo.2025.100148_bib15","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.3109\/10428194.2013.783911","article-title":"Emerging drug profile: cyclin-dependent kinase inhibitors","volume":"54","author":"Blachly","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.bneo.2025.100148_bib16","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41375-022-01758-z","article-title":"VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemia","volume":"37","author":"Sher","year":"2023","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.bneo.2025.100148_bib17","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.bbamcr.2015.08.015","article-title":"Advances in understanding the acute lymphoblastic leukemia bone marrow microenvironment: from biology to therapeutic targeting","volume":"1863","author":"Chiarini","year":"2016","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"10.1016\/j.bneo.2025.100148_bib18","first-page":"1164","article-title":"The bone marrow microenvironment as a mediator of chemoresistance in acute lymphoblastic leukemia","volume":"2","author":"Meyer","year":"2019","journal-title":"Cancer Drug Resist"},{"issue":"6","key":"10.1016\/j.bneo.2025.100148_bib19","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/bjh.12205","article-title":"MLL-rearranged acute lymphoblastic leukaemia stem cell interactions with bone marrow stroma promote survival and therapeutic resistance that can be overcome with CXCR4 antagonism","volume":"160","author":"Sison","year":"2013","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.bneo.2025.100148_bib20","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.blre.2017.03.004","article-title":"The bone marrow microenvironment \u2013 home of the leukemic blasts","volume":"31","author":"Shafat","year":"2017","journal-title":"Blood Rev"},{"issue":"1","key":"10.1016\/j.bneo.2025.100148_bib21","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ccr.2008.05.003","article-title":"Menin critically links MLL proteins with LEDGF on cancer- associated target genes","volume":"14","author":"Yokoyama","year":"2008","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.bneo.2025.100148_bib22","doi-asserted-by":"crossref","DOI":"10.1038\/s41420-022-01093-3","article-title":"Effective tumor cell abrogation via Venetoclax-mediated BCL-2 inhibition in KMT2A-rearranged acute B-lymphoblastic leukemia","volume":"8","author":"Richter","year":"2022","journal-title":"Cell Death Discov"},{"issue":"12","key":"10.1016\/j.bneo.2025.100148_bib23","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1016\/j.celrep.2015.12.003","article-title":"MLL-rearranged acute lymphoblastic leukemias activate BCL-2 through H3K79 methylation and are sensitive to the BCL-2-specific antagonist ABT-199","volume":"13","author":"Benito","year":"2015","journal-title":"Cell Rep"},{"issue":"23","key":"10.1016\/j.bneo.2025.100148_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242316708","article-title":"Recent updates in venetoclax combination therapies in pediatric hematological malignancies","volume":"24","author":"Le\u015bniak","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"11","key":"10.1016\/j.bneo.2025.100148_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1000249","article-title":"Misguided transcriptional elongation causes mixed lineage leukemia","volume":"7","author":"Mueller","year":"2009","journal-title":"PLoS Biol"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2025.100148_bib26","doi-asserted-by":"crossref","first-page":"10685","DOI":"10.1182\/blood-2022-169917","article-title":"Preclinical study of enitociclib, a selective CDK9 inhibitor, in combination with bortezomib, lenalidomide, pomalidomide, or venetoclax in the treatment of multiple myeloma","volume":"140","author":"Tran","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bneo.2025.100148_bib27","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.leukres.2014.11.004","article-title":"C-Myc plays part in drug resistance mediated by bone marrow stromal cells in acute myeloid leukemia","volume":"39","author":"Xia","year":"2015","journal-title":"Leuk Res"},{"issue":"6","key":"10.1016\/j.bneo.2025.100148_bib28","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood-2016-02-699363","article-title":"JAK1\/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell\u2013induced protection of AML","volume":"130","author":"Karjalainen","year":"2017","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.bneo.2025.100148_bib29","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.neo.2014.10.002","article-title":"Regulation of Mcl-1 expression in context to bone marrow stromal microenvironment in chronic lymphocytic leukemia","volume":"16","author":"Balakrishnan","year":"2014","journal-title":"Neoplasia (United States)"},{"issue":"3","key":"10.1016\/j.bneo.2025.100148_bib30","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/sj.leu.2403253","article-title":"In vitro drug-resistance profile in infant acute lymphoblastic leukemia in relation to age, MLL rearrangements and immunophenotype","volume":"18","author":"Ramakers-van Woerden","year":"2004","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.bneo.2025.100148_bib31","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1038\/leu.2011.388","article-title":"Elevated S100A8\/S100A9 expression causes glucocorticoid resistance in MLL-rearranged infant acute lymphoblastic leukemia","volume":"26","author":"Spijkers-Hagelstein","year":"2012","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.bneo.2025.100148_bib32","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1182\/blood-2009-02-205963","article-title":"Association of high-level MCL-1 expression with in vitro and in vivo prednisone resistance in MLL-rearranged infant acute lymphoblastic leukemia","volume":"115","author":"Stam","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bneo.2025.100148_bib33","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13045-019-0749-y","article-title":"Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia","volume":"12","author":"Brzezinka","year":"2019","journal-title":"J Hematol Oncol"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328025000834?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328025000834?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T01:42:19Z","timestamp":1764121339000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328025000834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S2950328025000834"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2025.100148","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting CDK9 inhibits the growth of KMT2A-rearranged infant leukemia and demonstrates synergy with menin inhibition","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2025.100148","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100148"}}